ATE402192T1 - Anti-ccr4 antikörper und fragmente davon - Google Patents

Anti-ccr4 antikörper und fragmente davon

Info

Publication number
ATE402192T1
ATE402192T1 AT01908280T AT01908280T ATE402192T1 AT E402192 T1 ATE402192 T1 AT E402192T1 AT 01908280 T AT01908280 T AT 01908280T AT 01908280 T AT01908280 T AT 01908280T AT E402192 T1 ATE402192 T1 AT E402192T1
Authority
AT
Austria
Prior art keywords
ccr4
antibody fragment
antibody
recombinant antibody
cell
Prior art date
Application number
AT01908280T
Other languages
English (en)
Inventor
Kenya Shitara
Nobuo Hanai
Emi Hosaka
Mikiko Sakurada
Akiko Furuya
Kazuyasu Nakamura
Rinpei Niwa
Kenji Shibata
Motoo Yamasaki
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE402192T1 publication Critical patent/ATE402192T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01908280T 2000-03-03 2001-03-02 Anti-ccr4 antikörper und fragmente davon ATE402192T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000059508 2000-03-03
JP2000401563 2000-12-28

Publications (1)

Publication Number Publication Date
ATE402192T1 true ATE402192T1 (de) 2008-08-15

Family

ID=26586785

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01908280T ATE402192T1 (de) 2000-03-03 2001-03-02 Anti-ccr4 antikörper und fragmente davon

Country Status (15)

Country Link
US (4) US6989145B2 (de)
EP (2) EP1992644A1 (de)
JP (1) JP3926153B2 (de)
KR (1) KR100890873B1 (de)
CN (1) CN100455599C (de)
AT (1) ATE402192T1 (de)
AU (2) AU2001236073B2 (de)
CA (1) CA2401491C (de)
CY (1) CY1108397T1 (de)
DE (1) DE60134962D1 (de)
DK (1) DK1270595T3 (de)
ES (1) ES2309050T3 (de)
PT (1) PT1270595E (de)
SI (1) SI1270595T1 (de)
WO (1) WO2001064754A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) * 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
MXPA03008001A (es) * 2001-03-06 2004-10-15 Dow Chemical Co Celula vegetal que tiene funcion de adicion de cadena de azucar tipo animal.
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
ES2321065T3 (es) * 2001-04-26 2009-06-02 Biogen Idec Ma Inc. Anticuerpos bloqueantes de cripto y usos de los mismos.
MXPA04001894A (es) 2001-08-31 2005-09-08 Kyowa Hakko Kogyo Kk Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo.
US7541040B2 (en) 2001-12-04 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Serivces Chimeric molecule for the treatment of th2-like cytokine mediated disorders
EP1491209A4 (de) * 2002-02-28 2006-05-17 Kyowa Hakko Kogyo Kk Mittel für die diagnose und behandlung der interstitiellen pneumonie
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
WO2004072646A1 (en) * 2003-02-13 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5)
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
US8496930B2 (en) 2003-10-01 2013-07-30 Kyowa Hakko Kirin Co., Ltd Method of stabilizing antibody and stabilized solution-type antibody preparation
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
FR2861395B1 (fr) 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
JPWO2005053742A1 (ja) * 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
DE602004029934D1 (de) 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell
AU2006203889A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. CRIPTO binding molecules
EP2175016A4 (de) * 2007-06-25 2012-03-28 Forerunner Pharma Res Co Ltd Anti-prominin-1-antikörper mit adcc-aktivität oder cdc-aktivität
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
JP5552630B2 (ja) * 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
WO2011038159A2 (en) * 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
EP2543727B1 (de) 2010-03-02 2016-08-31 Kyowa Hakko Kirin Co., Ltd. Modifizierte antikörperzusammensetzung
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
EP2652498B1 (de) 2010-12-16 2018-04-18 F.Hoffmann-La Roche Ag Diagnose und behandlungen im zusammenhang mit th2-hemmung
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
EP3626739A1 (de) 2011-06-24 2020-03-25 Stephen D. Gillies Leichtkettige immunglobulinfusionsproteine und verfahren zur verwendung davon
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
CA2877848C (en) * 2012-07-06 2021-11-02 St. Marianna University School Of Medicine Therapeutic method and medicament for htlv-1 associated myelopathy (ham)
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
EP3683232A1 (de) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Verfahren und zusammensetzungen mit gereinigten rekombinanten polypeptiden
AU2015328273B2 (en) * 2014-10-06 2020-09-17 Dana-Farber Cancer Institute, Inc. Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
TW201713332A (zh) 2015-07-14 2017-04-16 協和醱酵麒麟有限公司 包含與抗體組合投予之ｉｄｏ抑制物之腫瘤治療劑
US11207690B2 (en) 2015-12-22 2021-12-28 3M Innovative Properties Company Stem-well films for sample partitioning
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US12053512B2 (en) 2016-12-08 2024-08-06 Nantbio, Inc. Method of validating the triggering of an immune response to a neoepitope of a tumor with t-cells
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
WO2019154776A1 (en) 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
WO2019178601A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Peptide vaccines against interleukin-31
KR20250026872A (ko) 2018-03-16 2025-02-25 조에티스 서비시즈 엘엘씨 수의학적 용도를 위한 인터류킨-31 단클론성 항체
EP3773717A4 (de) * 2018-03-29 2022-05-11 REMD Biotherapeutics, Inc. Behandlung von autoimmun- und entzündungserkrankungen mit antikörpern, die interleukin-17a (il-17a) binden
SG11202103064YA (en) 2018-10-29 2021-05-28 Hoffmann La Roche Antibody formulation
WO2020106886A1 (en) 2018-11-20 2020-05-28 Cornell University Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US19341A (en) * 1858-02-16 Louis beauche
US160015A (en) * 1875-02-23 Improvement in devices for cutting out sheet-metal washers
US187930A (en) * 1877-02-27 Improvement in processes of preserving meat
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH0853355A (ja) 1994-08-12 1996-02-27 Taisho Pharmaceut Co Ltd Ｉｌ−５産生抑制剤
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
PL318594A1 (en) * 1995-06-07 1997-06-23 Icos Corp Chemokine and analogues thereof originating from macrophages
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
AU690474B2 (en) * 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
CN1511519A (zh) 1997-11-12 2004-07-14 - 2型t辅助细胞介导的免疫病的治疗
US6355244B1 (en) * 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
TWI234464B (en) * 1998-06-26 2005-06-21 Chugai Pharmaceutical Co Ltd Medicine constituents for hypercalcemic crisis
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
EP1050307A1 (de) 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 Antagoniste in Sepsis
MXPA04001894A (es) 2001-08-31 2005-09-08 Kyowa Hakko Kogyo Kk Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo.
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
DE602004029934D1 (de) * 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell

Also Published As

Publication number Publication date
ES2309050T3 (es) 2008-12-16
CY1108397T1 (el) 2014-02-12
US6989145B2 (en) 2006-01-24
JP3926153B2 (ja) 2007-06-06
CN1407993A (zh) 2003-04-02
KR100890873B1 (ko) 2009-03-31
US8197814B2 (en) 2012-06-12
AU2001236073B2 (en) 2006-10-19
WO2001064754A1 (en) 2001-09-07
EP1270595A1 (de) 2003-01-02
SI1270595T1 (sl) 2008-12-31
CA2401491C (en) 2011-07-05
DK1270595T3 (da) 2008-11-10
EP1270595B1 (de) 2008-07-23
CN100455599C (zh) 2009-01-28
US7666418B2 (en) 2010-02-23
EP1992644A1 (de) 2008-11-19
KR20020089377A (ko) 2002-11-29
CA2401491A1 (en) 2001-09-07
US20120276090A1 (en) 2012-11-01
PT1270595E (pt) 2008-09-16
US20050187380A1 (en) 2005-08-25
AU3607301A (en) 2001-09-12
EP1270595A4 (de) 2005-07-27
US20100221178A1 (en) 2010-09-02
US20020098527A1 (en) 2002-07-25
US8632996B2 (en) 2014-01-21
DE60134962D1 (de) 2008-09-04

Similar Documents

Publication Publication Date Title
DE60134962D1 (de) Anti-ccr4 antikörper und fragmente davon
EA200500497A3 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИ-IFN-γ НЕЙТРАЛИЗУЮЩИЕ АНТИТЕЛА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ ИНГИБИТОРОВ ПУТЕЙ IFN-γ
WO2001064751A3 (en) High potency recombinant antibodies and method for producing them
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
MA28418B1 (fr) Anticorps liant un recepteur de l'interleucine 4
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
MXPA03000103A (es) Antigenos de streptococcus.
EA200500441A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
ATE443139T1 (de) Menschliche toll-ähliche rezeptorproteine, zugehörige reagenzien und verfahren
ATE407147T1 (de) Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
PE20030473A1 (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular
IL144265A0 (en) Use of antibodies for the vaccination against cancer
SE0302312D0 (sv) Peptide-based passive immunization therapy for treatment of atherosclerosis
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
ATE537257T1 (de) Mit iga-nephropathie assoziierte dns
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis
WO2001079434A3 (en) A novel polypeptide, a human signal peptidase 10 and the polynucleotide encoding the polypeptide
WO2001075021A3 (fr) Nouveau polypeptide, proteine humaine associee au transport de glucose 10, et polynucleotide codant pour ce polypeptide
WO2001075010A3 (fr) Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1270595

Country of ref document: EP

EEFA Change of the company name